Alexion Pharmaceuticals Inc. acquired Taligen Therapeutics Inc. for $111 million up front with additional contingent payments based on clinical and regulatory milestones. Alexion ended 2010 with $297 million in the bank, so the Taligen acquisition was an affordable move allowing it to neutralize a future competitor and diversify its pipeline.